Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Somewhat Bearish -25

Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds

AI-generated analysis

📉 Low-dose tirzepatide achieved 5.5% weight loss over one year versus only 2.2% for low-dose semaglutide, highlighting a significant efficacy gap at starter doses.

💊 Patients on lower doses experienced fewer side effects like nausea but faced other adverse events including kidney injury and muscle cramps with tirzepatide.

📈 The obesity drug market is projected to exceed $100 billion annually by 2030, driving competition between Novo Nordisk and Eli Lilly.

🔬 Novo Nordisk's CagriSema demonstrated less weight loss than Lilly's Zepbound in head-to-head testing, reinforcing Lilly's competitive lead.

💰 Hedge fund positions surged for Eli Lilly to $17.24 billion while Novo Nordisk saw a more modest rise to $2.00 billion in the second quarter.

🚀 Novo Nordisk is pursuing oral obesity treatments like Wegovy pills to diversify beyond injections as the global market expands.

⚠️ Substantially lower weight loss at starter doses could limit revenue per patient if users avoid higher maintenance doses due to cost or tolerability.

🏥 Lilly's tirzepatide showed higher rates of constipation and muscle cramps compared to semaglutide, influencing physician and patient preferences.

📊 Novo Nordisk faces pressure from Lilly despite the expanding market, requiring its pipeline and oral treatments to regain momentum.

🌍 Both companies benefit from wider treatment access enabled by low-dose options, though this may come at the expense of treatment intensity.

Bullish Signals
  • Novo Nordisk's Wegovy pill offers a strategic opportunity to compete in the expanding oral obesity market beyond injections.
  • The company expects its oral formulations to become a significant part of future GLP-1 usage as per CEO projections.
  • Low-dose semaglutide still enables measurable weight loss (2.2%) at starter doses, supporting broader patient access and treatment adoption.
  • Novo Nordisk is developing next-generation pipeline assets like CagriSema to address competitive pressures from Eli Lilly.
Risk Factors
  • Low-dose semaglutide produced only 2.2% weight loss versus 5.5% for low-dose tirzepatide, indicating inferior efficacy at starter doses.
  • Substantially lower weight loss at starter doses could limit revenue per patient if users avoid higher maintenance doses due to cost or tolerability.
  • Novo Nordisk's CagriSema produced less weight loss than Lilly's Zepbound in head-to-head testing, weakening its competitive position.
  • The company remains under pressure from Eli Lilly despite the expanding market, with Lilly outperforming on both injectable and oral metrics.
  • Hedge fund data shows a more modest rise in holdings for Novo Nordisk compared to the surge seen in Eli Lilly positions.
Full Analysis
A new study published in September 2026 reveals that patients on the lowest starter doses of GLP-1 weight-loss drugs still achieve measurable weight loss, though significantly less than at full recommended doses. Specifically, low-dose tirzepatide from Eli Lilly produced a 5.5% average weight loss over one year compared to 2.2% for Novo Nordisk's low-dose semaglutide. While lower doses reduce side effects like nausea, they also result in substantially reduced efficacy compared to higher therapeutic regimens. The research highlights a critical trade-off between tolerability and revenue potential for both companies. If patients remain on lower starter doses due to cost or side-effect concerns, prescription volume may grow without corresponding revenue growth per patient. This dynamic is particularly challenging for Novo Nordisk, whose low-dose semaglutide showed weaker performance relative to Lilly's tirzepatide in this specific dosage bracket. Despite these findings, the expanding obesity market presents significant opportunities for both firms, with analysts projecting the sector to exceed $100 billion annually by 2030. Novo Nordisk continues to pursue growth through its oral obesity treatments like Wegovy pills and next-generation pipeline assets such as CagriSema. However, Lilly's superior low-dose efficacy and existing market leadership in injectables maintain a competitive advantage that pressures Novo's strategic position. Investor sentiment reflects these dynamics, with hedge fund data showing a surge in holdings for Eli Lilly while Novo Nordisk sees more modest increases. The study underscores the importance of treatment intensity for revenue generation, suggesting that Novo must leverage its oral formulations and pipeline innovations to regain momentum against Lilly's dominant market share and stronger drug performance.